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Sleep/wake and circadian rest-activity rhythms become irregularwith age.Typical outcomes
include fragmented sleep during the night, advanced sleep phase syndrome and increased
daytime sleepiness. These changes lead to a reduction in the quality of life due to cogni-
tive impairments and emotional stress. More importantly, severely disrupted sleep and
circadian rhythms have been associated with an increase in disease susceptibility. Addi-
tionally, many of the same brain areas affected by neurodegenerative diseases include the
sleep and wake promoting systems. Any advances in our knowledge of these sleep/wake
and circadian networks are necessary to target neural areas or connections for therapy.
This review will discuss research that uses molecular, behavioral, genetic and anatomical
methods to further our understanding of the interaction of these systems.
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Studies have shown that sleep and circadian activity rhythms
become irregular with age (Morin, 1993; Valentinuzzi et al., 1997;
Kendall et al., 2001). Sleep becomes fragmented during the night
and daytime sleepiness increases (Carskadon et al., 1982; Huang
et al., 2002). The quantity of REM sleep and slow wave sleep
(SWS) decreases as well and the normal circadian amplitude of the
sleep/wake cycle is dampened and shortened (vanGool et al., 1987;
Turek et al., 1995). These changes lead to a reduction in the quality
of life due to cognitive impairments and emotional stress. More
importantly, severely disrupted sleep and circadian rhythms have
been associated with an increase in disease susceptibility (Hastings
et al., 2003; Gibson et al., 2009).
The mechanisms responsible for the development of frag-
mented sleep are not completely understood. However, examin-
ing the functional interaction between circadian oscillators and
sleep/wake areas has aided in these efforts (Dijk and von Schantz,
2005). With increasing age, circadian and sleep/wake neural areas
or connections within the network may compensate for initial
dysfunctions (Van Someren et al., 2002). For example, the degen-
eration of one network component may be deleterious on the
systems as a whole, while other components may be more resistant
to age-associated degeneration (Naidoo et al., 2011). Discerning
how systems change with age is important to understand how they
contribute to normal and dysfunctional sleep and wake. Many of
the same brain areas in the sleep and wake promoting systems
are affected by neurodegenerative diseases. Any advances in our
knowledge of these sleep/wake and circadian networks may aid in
designing therapies targeting these neural areas or connections.
This review will discuss research that uses molecular, behavioral,
genetic and anatomical methods to further our understanding of
the interaction of these systems.
AGING CIRCADIAN SYSTEMS
The desynchronization of central and peripheral circadian systems
contributes to the decline in optimal functioning of bodily sys-
tems. This includes changes in neuroendocrine circadian rhythms,
insulin sensitivity, altered thermoregulation and acceleration of
tumor growth (Cincotta et al., 1993; Touitou and Haus, 2000;
Hastings et al., 2003; Straub and Mocchegiani, 2004; Cretenet
et al., 2010;Heller et al., 2011). These are complex interactions and
dysfunction can be due to targeted disruption of neurons, neuro-
transmitter or neuropeptide production, transport or secretion. It
is reasonable to expect that the neuronal activity or expression of
circadian clock genes be reduced or rhythms phase shifted (Kolker
et al., 2003). Additionally, the connections between central and
peripheral oscillators may be degraded or less functional (Morales
et al., 1987). Any one or a combination of these abnormalities may
result in the decoupling of the circadian oscillators and the ensuing
pathologies.
The master central pacemaker is the suprachiasmatic nucleus
(SCN) which controls circadian rhythmicity. Rhythmicity can
dampen and/or elongate/shift with age but the number or cell
size of neurons in the SCN does not change. However, the oscil-
lating activity of these neurons does deteriorate (Satinoff et al.,
1993; Madeira et al., 1995). Additionally, glucose uptake decreases
in the SCN in aged animals (Wise et al., 1988) and the expression
of neuropeptides also diminishes. Vasoactive intestinal polypep-
tide (VIP) expressing neurons of the SCN are retinorecipient and
vasopressin (AVP) expressingneurons of the SCNmodulate rhyth-
micity (Wu et al., 2007). In aged male humans, the number of SCN
neurons that express VIP decreases and in aged female rats the
expression becomes arrhythmic (Zhou et al., 1995; Krajnak et al.,
1998). Both genders also express less AVP protein, less mRNA
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(Roozendaal et al., 1987; Zhou et al., 1995) and the normal day-
time peak of AVP is reduced (Hofman and Swaab, 1994; Liu et al.,
2000). Decreases in the neuroendocrine output of the SCN may
directly or indirectly affect the coupling of central and peripheral
oscillators.
In the SCN, clock genes constitute the core clock mechanism of
the mammalian timekeeping system. Though the system is fairly
complex, for brevity the simplest model is described. BMAL1 and
CLOCK proteins dimerize and induce the transcription of Period
(Per) and Cryptochrome (Cry) genes. In a negative feedback loop,
levels of PER and CRY proteins increase and at a certain threshold
form heterodimers which turn off the CLOCK BMAL1 regulated
transcription of Per andCry genes. This process takes roughly 24 h
(Ko and Takahashi, 2006).
In aged animals the expression of certain clock genes changes in
the SCN. Per1, Per2, and Cry1 expression does not change signiﬁ-
cantly with age, but the normal photic stimulation of Per1 expres-
sion is reduced (Asai et al., 2001; Kolker et al., 2003). Additionally,
the free-running period of Per1–luc rhythmicity is shortened in
aged animals (Yamazaki et al., 2002) and the amplitude of Clock
and Bmal1 expression is decreased (Kolker et al., 2003). Changes
in clock gene expression in peripheral tissues do not always reﬂect
what is seen in the SCN(Yamazaki et al., 2000), andmay result from
a disruption of signals to these tissues or the tissues themselves,
which are more susceptible to the aging process.
Furthermore, projections to and from the SCN including
peripheral oscillators may change with age. In motoneurons, aging
results in a shortening in delay of spike potentials between axon
and soma, as well as decreases in axon conduction velocity and
increases in input resistance (Morales et al., 1987; Engelhardt et al.,
1989). Similar changes may be seen in these circadian projections.
Light, food and temperature cues also input to the SCN. The out-
put from circadian and peripheral oscillators do not only inﬂuence
the sleep/wake cycle, but regulates metabolism and reproduction.
Studies indicate that some tissues retain the ability to oscillate, even
if connections from the master pacemaker have been degraded.
Peripheral tissues in vitro that have become arrhythmic can be
chemically induced to oscillate (Yamazaki et al., 2002). However,
in aged animals exhibiting a decreased photic response, retinal
projections to the SCN are not degraded and must be related to
either the retina or SCN clock functions (Zhang et al., 1998). It
is increasingly evident that determining the source of age-related
sleep/wake or circadian dysfunctions is rather complex.
SLEEP/WAKE SYSTEMS AGE
Another source of sleep/wake changes can likely be attributed to
age-related neuronal dysfunction in the arousal and sleep promot-
ing areas of the brain. The SCN directly or indirectly communi-
cates with the sleep and wake promoting systems (Abrahamson
et al., 2001; Aston-Jones et al., 2001; Chou et al., 2002). Orex-
inergic (or hypocretinergic) neurons are known to stabilize or
maintain wake (Saper et al., 2001, 2005). These cells receive input
from the SCN via the dorsomedial hypothalamus (DMH) and are
localized in the perifornical and lateral hypothalamus (LH). There
are two forms of the neuropeptide orexin/hypocretin (A and B)
and two receptors. Though the neurons are limited to a discrete
area, both orexinergic ﬁbers and receptors are widely distributed
throughout the brain. In diurnal and nocturnal rodents, orexiner-
gic neurons aremost active during the active phase (Martinez et al.,
2002). Hypothalamic microdialysate analysis shows orexin-1 lev-
els increase during wake and REM in adult animals (Kiyashchenko
et al., 2002).
Mammals with no orexin or dysfunctional orexin/hypocretin
receptors have disrupted sleep/wake cycles and narcoleptic symp-
toms. When orexin is decreased, the circadian rhythm of the
sleep/wake cycle is disrupted. The ﬂip–ﬂop model of sleep/wake
control suggests that there is a mutual inhibition between the areas
that control sleep and the areas that control the wake state (Saper
et al., 2001). In short, the ventrolateral preoptic area (VLPO)
controls sleep and the brainstem cholinergic and monoaminer-
gic systems control waking. Flipping weight between these areas
controls the wake and sleep states. One input that stabilizes this
switch is from the orexin neurons. Blocking or destroying these
neurons or the orexin receptor 2 may ﬂip the animal’s state quickly
from waking to sleep and vice versa, such as what occurs in
narcoleptic individuals, orexin knockout mice, and canine nar-
colepsy (Chemelli et al., 1999; Lin et al., 1999; Peyron et al., 2000;
Thannickal et al., 2000).
A disruption in orexin function or a reduction in orexin levels
leads to less stable sleep/wake cycles such as that seen in many
elderly patients with sleep disorders (Porkka-Heiskanen, 2003).
Additionally, decreases in excitatory orexin innervation to the
noradrenergic locus coeruleus (LC) is thought to be a contributing
factor of poor sleep/wake quality in aged cats (Zhang et al., 2002).
Orexin B immunoreactive (-ir) axon density was determined to be
signiﬁcantly lower in the LC of aged macaques than that observed
in the young or adult animals (43 and 35% decrease respectively;
Downs et al., 2007). Real time PCR studies showed that prepro-
hypocretin mRNA does not change in the aged hypothalamus
(Terao et al., 2002) but in situ hybridization studies show that
at the single cell level, preproorexin gene expression does decrease
in cell count and optical density (Porkka-Heiskanen et al., 2004).
Furthermore, orexin A and B protein expression as measured by
radioimmunoassay was decreased in the LH (Porkka-Heiskanen
et al., 2004). The number of orexinergic-ir neurons as well as the
optical density of respective ﬁbers in the LH is reduced in aged
animals (Brownell and Conti, 2010; Sawai et al., 2010). It is inter-
esting to note that orexinergic innervation of the cholinergic basal
forebrain, which modulates wake and REM sleep, is reduced in
aged guinea pigs (Zhang et al., 2005). Orexin/hypocretin receptor
mRNA expression is also decreased in aged animals. Hypocretin
receptor 1 mRNA is reduced in the hippocampus and hypocre-
tin receptor 2 mRNA is signiﬁcantly reduced in thalamic areas,
hippocampus, and the brainstem (Terao et al., 2002). Neural activ-
ity measured by c-fos immunoreactivity is reduced in orexinergic
neurons of mice at 24months (Naidoo et al., 2011).
Changes are also seen in the cholinergic and monoaminer-
gic wake active areas of aged animals. Nicotinic and muscarinic
receptors of the acetylcholinergic system decrease in the SCN with
age (van der Zee et al., 1991). In young animals, the noradrener-
gic neurons of the LC are important in wake promotion, receive
direct input from the SCN and follow a circadian pattern of activa-
tion (Aston-Jones et al., 2001). In aged rats, LC projections to the
frontal cortex and dentate gyrus decrease but axonal branching
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increases depending on the target and age. This is suggested to
be a compensatory mechanism (Shirokawa et al., 2000). In the
ventral periaqueductal gray (vPAG) the wake active dopaminer-
gic neurons have recently been identiﬁed (Lu et al., 2006). We
have recently reported a reduction in the neural activity of these
dopaminergic neurons of the vPAGand thenoradrenergic neurons
of the LC in aged mice (Naidoo et al., 2009, 2011).
The wake active histaminergic system originates in the tubero-
mammillary nucleus (TMN) and sends widespread projections to
areas that include the cortex, thalamus and brainstem. Histamine
levels were found to be increased in middle aged rats when com-
pared to young, and the level of histamine methyl transferase was
decreased (Mazurkiewicz-Kwilecki andPrell, 1984). Thehistamine
receptor mRNA levels also change with age. There are four types
of histaminergic receptors located throughout the brain and body.
Histamine H1, H2 and H3 receptor mRNA is decreased in the
aging brain (Terao et al., 2004). Given these changes in the aging
wake promoting neurotransmitter systems as well as wake main-
taining systems, it is clear that therapies to alleviate or attenuate
these changes need to be developed.
Sleep promoting areas may show a reduction in function with
age. TheVLPO neurons are active during SWS (Sherin et al., 1996;
Szymusiak et al., 1998) and when lesioned results in insomnia
(Lu et al., 2000). GABAergic and galaninergic inhibitory neurons
from this area project towake active histaminergic neurons (Sherin
et al., 1996). Interestingly, the number of activated VLPO neurons
during sleep does not change in old rats (Shiromani et al., 2000)
although connections between these areas may become dysfunc-
tional or degraded with age. The SCN has a minor input into
the VLPO, but substantial direct and indirect inputs to the DMH
(Novak and Nunez, 2000; Chou et al., 2002). The DMH heavily
inputs the VLPO and it would be beneﬁcial if these pathways were
examined during aging.
Age-associated changes in the serotonergic system affect the
function of respiratory motor output during sleep. Serotonergic
input to the hypoglossal nucleus decreases, which is thought to
lead to a decline in upper airway muscle performance (Behan and
Brownﬁeld, 1999). In aged rhesus monkeys, serotonin receptor 2
density reduces in the occipital and parietal cortex including the
deep layers of the motor cortex (Wenk et al., 1989; Bigham and
Lidow, 1995). Serotonin levels also decrease in the occipital areas
but do not change in the cingulate cortex in aged monkeys (Beal
et al., 1991). It is likely with normal aging that changes in any neu-
rotransmitter system affecting sleep vary across the brain. This
presents a difﬁcult task to fully determine the interaction of aging
and sleep.
AGE-ASSOCIATED NEURODEGENERATIVE DISEASES AND
SLEEP
In many patients afﬂicted with neurodegenerative diseases the
physical andmental consequences lead to sleepdisorders (Table 1).
For example, sleep fragmentation can occur if the patient cannot
move well or insomnia may develop due to depression or feelings
of helplessness. Medications used to alleviate some of the motor or
cognitive symptoms such as levodopa in Parkinson’s disease (PD)
can also contribute to disruptions in normal sleep/wake behav-
iors. Sleep disorders may occur secondarily or due to concurrent
or related neurodegenerative pathologies. However, some research
indicates that sleepdisturbancesmaypredictmanifestationof neu-
rodegenerative diseases (Postuma and Montplaisir, 2009). Sleep
disturbance or loss also affects metabolic and immune function
(Krueger et al., 1998; Knutson et al., 2007). Chronic sleep loss
could lead to neuronal damage resulting in altered hypothalamic
pituitary adrenal axis function, cognitive deﬁcits andmemory loss.
Increases in the number of patients with neurodegenerative dis-
eases may be related to or the result of a society that does not
sleep.
In Alzheimer’s disease (AD), sleep disturbances increase with
the severity of the disease. Initially there is an increase in night-
time arousals and a decrease in SWS (Vitiello et al., 1991). In the
later stages, circadian disruption, severe daytimewakefulness and a
reduction in REM sleep occurs, likely due to a reduction in acetyl-
choline (Dykierek et al., 1998). Circadian rhythm dysfunction has
been proposed to be due to changes in SCN and pineal func-
tions (Wu et al., 2007). Degeneration of cholinergic input from
the nucleus basalis of Meynert to the cortex may be responsible
for some of the sleep/wake changes (Montplaisir et al., 1995). Neu-
roﬁbrillary tangles found in the histaminergicTMNofADpatients
and amyloid-βpeptide (Aβ) aggregation also contributes to theAD
pathology. Normally in the interstitial ﬂuid Aβ has a diurnal ﬂuc-
tuation with low levels during sleep and peak levels during wake.
Recently one study showed that prolonged wake and/or orexin
administration increased levels of the Aβ in the interstitial ﬂuid
of the brain in mice (Kang et al., 2009). Administration of an
orexin antagonist reduced amyloid deposits in several brain areas
suggesting that manipulating sleep or the orexin system in AD
patients could improve symptoms (Kang et al., 2009). Although
the research is sparse, melatonin, phototherapy and exercise have
all had positive effects in the treatment of circadian and sleep/wake
disorders of AD patients (Wu and Swaab, 2007). As one in three
Americans develops AD, there is a crucial need for more research
in these therapies.
REM sleep behavior disorder (RBD) has been associated with
PD and thought to be an early manifestation (Schenck et al., 1996;
Boeve et al., 2003; Postuma and Montplaisir, 2009). Sleep attacks
and excessive daytime sleepiness (EDS) are also commonly seen
in patients with PD (Factor et al., 1990; Diederich et al., 2005).
The degeneration begins at the brainstem and progresses ros-
trally, although degeneration of the dopaminergic neurons of the
substantia nigra pars compacta is the main contributor to PD
characteristics (Braak et al., 2004). RBD results from pedunculo-
pontine dysfunction and likely explains RBDmanifesting previous
to PD (Rye, 1997; Boeve et al., 2007). Some studies have success-
fully seen bright light therapy or sleep modiﬁcations reduce the
symptoms of PD (Hogl et al., 1998; Willis and Turner, 2007).
Huntington’s disease (HD) is a genetic disorder characterized
by a polyglutamine (CAG) repeat (Scherzinger et al., 1999). Neu-
rodegeneration is extensive throughout the brain, affecting cortical
and subcortical areas but primarily affects the basal ganglia (Von-
sattel et al., 1985). Sleep andwake regions of the brain including the
brainstem, thalamus, hypothalamus and cortex are also affected in
HD (Kremer et al., 1991). The SCN pacemaker is functional in
mouse models of HD, so a dysfunction of the circadian circuitry
is proposed to contribute to circadian abnormalities (Pallier et al.,
www.frontiersin.org October 2011 | Volume 2 | Article 66 | 3
Singletary and Naidoo Degeneration of sleep and circadian neural networks
Ta
b
le
1
|C
o
m
m
o
n
sl
ee
p
an
d
w
ak
e
ch
ar
ac
te
ri
st
ic
s
o
f
n
eu
ro
d
eg
en
er
at
iv
e
d
is
ea
se
s.
B
ra
in
ar
ea
s,
n
eu
ro
n
s
d
am
ag
ed
G
en
er
al
P
u
ta
ti
ve
p
re
d
ic
ti
ve
fa
ct
o
rs
C
ir
ca
d
ia
n
N
R
E
M
R
E
M
W
ak
e
T
h
er
ap
eu
ti
c
in
te
rv
en
ti
o
n
s
A
ge
-
as
so
ci
at
ed
de
ge
ne
ra
tio
n
B
as
al
fo
re
br
ai
n,
LC
,
ce
re
br
al
co
rt
ex
;D
A
,
or
ex
in
1,
2,
3
;c
ho
lin
er
gi
c
re
ce
pt
or
s4
P
ha
se
ad
va
nc
ed
,
fr
ag
m
en
te
d
sl
ee
p
an
d
w
ak
e,
E
D
S
5,
6
D
is
ru
pt
ed
m
el
at
on
in
sy
st
em
7,
8
A
lte
re
d
ci
rc
ad
ia
n
re
st
-a
ct
iv
ity
rh
yt
hm
s9
,1
0
;a
lte
re
d
pe
rip
he
ra
l
re
sy
nc
hr
on
iz
at
io
n1
1
D
ec
re
as
ed
S
W
S
12
D
ec
re
as
ed
R
E
M
12
,1
3,
14
Fr
ag
m
en
te
d
w
ak
e,
in
cr
ea
se
d
na
pp
in
g,
E
D
S
6,
10
P
ho
to
th
er
ap
y1
5
A
lz
he
im
er
’s
di
se
as
e
B
as
al
fo
re
br
ai
n;
ce
re
br
al
co
rt
ex
;A
C
h1
6,
17
D
ec
re
as
ed
to
ta
ls
le
ep
tim
e1
8
R
E
M
de
ns
ity
13
D
is
ru
pt
ed
co
re
-b
od
y
te
m
pe
ra
tu
re
rh
yt
hm
19
;d
is
ru
pt
ed
m
el
at
on
in
sy
st
em
20
D
ec
re
as
ed
S
W
S
18
;
de
cr
ea
se
d
sl
ee
p
sp
in
dl
es
21
D
ec
re
as
ed
R
E
M
13
;
in
cr
ea
se
d
iN
O
S
du
rin
g
R
E
M
22
Fr
ag
m
en
te
d
w
ak
e,
in
cr
ea
se
d
na
pp
in
g2
3
P
ho
to
th
er
ap
y,
ex
er
ci
se
24
;
or
ex
in
/h
yp
oc
re
tin
an
ta
go
ni
st
in
m
ic
e2
5
Pa
rk
in
so
n’
s
di
se
as
e
S
ub
st
an
tia
ni
gr
a
pa
rs
co
m
pa
ct
a;
D
A
26
;
O
re
xi
n2
7
S
le
ep
fr
ag
m
en
ta
tio
n2
8
;
R
B
D
29
R
E
M
be
ha
vi
or
di
so
rd
er
29
,3
0
D
ec
re
as
ed
di
ur
na
l
va
ria
tio
n
of
co
rt
is
ol
31
;
al
te
re
d
ci
rc
ad
ia
n
re
st
-a
ct
iv
ity
rh
yt
hm
s9
D
ec
re
as
ed
S
W
S,
de
cr
ea
se
d
sl
ee
p
sp
in
dl
es
32
R
B
D
29
;i
nt
ru
si
on
of
R
E
M
in
to
N
R
E
M
33
E
D
S
34
P
ho
to
th
er
ap
y3
5
H
un
tin
gt
on
’s
di
se
as
e
B
as
al
ga
ng
lia
;D
A
36
,3
7
Fr
ag
m
en
te
d
sl
ee
p
an
d
w
ak
e,
de
cr
ea
se
d
R
E
M
38
In
cr
ea
se
d
sl
ee
p
sp
in
dl
es
32
D
is
ru
pt
io
n
as
so
ci
at
ed
w
ith
in
cr
ea
se
d
no
ct
ur
na
la
ct
iv
ity
39
;
de
la
ye
d
sl
ee
p
ph
as
e4
2
C
ho
re
a
du
rin
g
st
ag
e
14
0
;
in
cr
ea
se
d
st
ag
e
13
8
;i
nc
re
as
ed
sl
ee
p
sp
in
dl
es
32
,4
1
D
ec
re
as
ed
R
E
M
,i
nc
re
as
ed
la
te
nc
y
to
R
E
M
38
W
ak
e
is
im
pa
ire
d
bu
t
re
po
rt
s
th
at
ar
e
di
ffe
re
nt
fr
om
ag
e-
m
at
ch
ed
co
nt
ro
ls
ar
e
no
t
co
ns
is
te
nt
41
,4
2
Fo
od
en
tr
ai
nm
en
t4
3
;
al
pr
az
ol
am
to
re
st
or
e
ci
rc
ad
ia
n
rh
yt
hm
s
sl
ow
s
co
gn
iti
ve
de
cl
in
e4
4
A
m
yo
tr
op
hi
c
la
te
ra
l
sc
le
ro
si
s
M
ot
or
ne
ur
on
s
of
th
e
m
ot
or
co
rt
ex
,
br
ai
ns
te
m
,a
nd
sp
in
al
co
rd
;p
ro
gr
es
si
ve
de
ge
ne
ra
tio
n
of
5H
T
ne
ur
on
s
co
nt
rib
ut
es
to
de
cr
ea
se
d
m
ot
on
eu
ro
n
ac
tiv
ity
45
S
D
B
,i
ns
om
ni
a4
6,
47
;
re
du
ce
d
qu
al
ity
of
sl
ee
p
co
rr
el
at
ed
w
ith
th
e
se
ve
rit
y
of
th
e
di
se
as
e4
8
;
de
ge
ne
ra
tio
n
le
ad
s
to
m
us
cl
e
w
ea
kn
es
s
an
d
S
D
B
46
S
D
B
(p
re
di
ct
iv
e
of
ea
rly
re
sp
ira
to
ry
fa
ilu
re
)4
6
D
is
ru
pt
ed
co
rt
is
ol
ci
rc
ad
ia
n
rh
yt
hm
49
D
ec
re
as
ed
S
W
S
48
D
ec
re
as
ed
an
d
fr
ag
m
en
te
d
R
E
M
sl
ee
p4
8
;
sl
ee
p
di
so
rd
er
ed
br
ea
th
in
g4
6
E
D
S
48
,5
0
C
PA
P
50
,5
1
;B
iP
A
P
52
;
m
el
at
on
in
su
pp
le
m
en
ta
tio
n5
3
D
A
,d
op
am
in
e;
iN
O
S,
in
du
ci
bl
e
ni
tr
ic
ox
id
e
sy
nt
ha
se
.
1
S
tu
rr
oc
k
an
d
R
ao
(1
98
5)
,
2
Zh
an
g
et
al
.
(2
00
5)
,
3
N
ai
do
o
et
al
.
(2
01
1)
,
4
va
n
de
r
Ze
e
et
al
.
(1
99
1)
,
5
C
ar
sk
ad
on
et
al
.
(1
98
2)
,
6
Fo
le
y
et
al
.
(2
00
7)
,
7
M
ag
ri
et
al
.
(1
99
7)
,
8 T
ou
ito
u
(1
99
5)
,
9 W
hi
te
he
ad
et
al
.
(2
00
8)
,
10
H
ua
ng
et
al
.(
20
02
),
11
D
av
id
so
n
et
al
.(
20
08
),
12
Tu
re
k
et
al
.(
19
95
),
13
D
yk
ie
re
k
et
al
.(
19
98
),
14
Fe
in
be
rg
et
al
.(
19
67
),
15
M
ye
rs
an
d
B
ad
ia
(1
99
5)
,1
6
B
ru
n
an
d
E
ng
lu
nd
(1
98
1)
,1
7 T
ei
pe
le
ta
l.
(2
00
5)
,1
8 V
iti
el
lo
et
al
.(
19
91
),
19
S
at
lin
et
al
.
(1
99
5)
,
20
W
u
et
al
.
(2
00
7)
,
21
M
on
tp
la
is
ir
et
al
.
(1
99
5)
,
22
Ts
en
g
et
al
.
(2
01
0)
,
23
B
on
an
ni
et
al
.
(2
00
5)
,
24
W
u
an
d
Sw
aa
b
(2
00
7)
,
25
K
an
g
et
al
.
(2
00
9)
,
26
B
ra
ak
et
al
.
(2
00
4)
,
27
Th
an
ni
ck
al
et
al
.
(2
00
7)
,
28
Fa
ct
or
et
al
.
(1
99
0)
,
29
S
ch
en
ck
et
al
.(
19
96
),
30
Po
st
um
a
an
d
M
on
tp
la
is
ir
(2
00
9)
,3
1
H
ar
tm
an
n
et
al
.(
19
97
),
32
E
m
se
r
et
al
.(
19
88
),
33
M
ou
re
t
(1
97
5)
,3
4
D
ie
de
ric
h
et
al
.(
20
05
),
35
W
ill
is
an
d
Tu
rn
er
(2
00
7)
,3
6 V
on
sa
tt
el
et
al
.(
19
85
),
37
K
re
m
er
et
al
.
(1
99
1)
,3
8
A
rn
ul
f
et
al
.(
20
08
),
39
M
or
to
n
et
al
.(
20
05
),
40
Fi
sh
et
al
.(
19
91
),
41
W
ie
ga
nd
et
al
.(
19
91
),
42
A
zi
z
et
al
.(
20
10
),
43
M
ay
w
oo
d
et
al
.(
20
10
),
44
Pa
lli
er
et
al
.(
20
07
),
45
S
an
dy
k
(2
00
6)
,4
6
K
im
ur
a
et
al
.(
19
99
),
47
A
ta
la
ia
et
al
.
(2
00
7)
,4
8
Lo
C
oc
o
et
al
.(
20
11
),
49
Pa
ta
cc
hi
ol
ie
t
al
.(
20
03
),
50
B
ar
th
le
n
an
d
La
ng
e
(2
00
0)
,5
1
H
ow
ar
d
et
al
.(
19
89
),
52
D
av
id
et
al
.(
19
97
),
53
W
ei
sh
au
pt
et
al
.(
20
06
).
Frontiers in Neurology | Sleep and Chronobiology October 2011 | Volume 2 | Article 66 | 4
Singletary and Naidoo Degeneration of sleep and circadian neural networks
2007). Central and peripheral clock gene expression is altered as
well (Morton et al., 2005; Maywood et al., 2010). The sleep/wake
cycle is disrupted in HD patients characterized by self-reported
EDS, sleep fragmentation at night, and delayed sleep phase (Arnulf
et al., 2008;Videnovic et al., 2009; Aziz et al., 2010). Sleep is lighter
with an increase in Stage 1 and a decrease in REM sleep (Arnulf
et al., 2008). Disruptions in the circadian and sleep/wake cycles of
these patients exacerbate symptoms, increasing depression, cog-
nitive deﬁcits and metabolic dysfunctions (Aziz et al., 2010). It is
important to note that pharmacological and behavioral manipu-
lation of sleep and wake reduces disease progression and improves
cognitive function and circadian gene expression in amousemodel
of HD (Hockly et al., 2002; Pallier et al., 2007; Pallier and Morton,
2009; Maywood et al., 2010).
Amyotrophic lateral sclerosis (ALS) is considered an age-
associated neurodegenerative disease with the age of onset ranging
from 40 to 70. Although onset can occur in children this is rare.
Most ALS cases are sporadic and about 10% are familial. Also
called Lou Gehrig’s or motor neuron disease (Boillee et al., 2006),
both upper and lower motor neurons are affected. Motor neu-
rons of the motor cortex, brainstem and spinal cord gradually
degenerate leading to muscle weakness, sleep disordered breath-
ing (SDB) and paralysis (Kimura et al., 1999). Additionally, sleep is
reduced in bothREMandSWS stageswith resultingEDS (Barthlen
and Lange, 2000; Lo Coco et al., 2011). Some patients ﬁnd relief
using assisted breathing such as continuous positive airway pres-
sure (CPAP) or bilevel positive airway pressure (BiPAP; Howard
et al., 1989; David et al., 1997; Barthlen and Lange, 2000).
Amyotrophic lateral sclerosis is a complex disease of many
subtypes with various genetic and environmental contribut-
ing factors. One such factor is glutamate toxicity which is
decreased using the drug Riluzole (Shaw and Ince, 1997). Alter-
native therapies are also being considered including the regula-
tion of the serotonin system. Levels of serotonin are decreased
in ALS patients and compensatory increases in glutamate lead
to excitotoxicity. It has been suggested that motor neurons
with a high density of serotonergic innervation are more sus-
ceptible to degeneration (Sandyk, 2006). Serotonin is the pre-
cursor to melatonin, which is also likely to be decreased. As
melatonin has antioxidant properties and inhibits glutamate
release, this reduction would further exacerbate degeneration.
Indeed, melatonin supplements slowed disease progression when
given to a mouse model of familial ALS (Weishaupt et al.,
2006).
PLASTICITY AND COMPENSATION
Normally the SCN is coupled to peripheral oscillators, although
studies have shown that SCN control is not necessary for sustain-
ing oscillatory activity. If signals from central oscillators reduce in
strength due to age or neurodegeneration, other cues may entrain
the peripheral oscillators (Weinert, 2005). Unmasking mecha-
nismswithin sleep/wake systems is difﬁcult due to themany checks
and balances that ensure homeostasis. Although compensation
and plasticity occurs to a lesser extent in older animals, a rela-
tively high degree is preserved (Van Someren et al., 2002). This
may not always be advantageous as epigenetic methylation of cir-
cadian genes has been associated with dementia (Liu et al., 2008).
Understanding how the aging brain can compensate and remain
plastic will be beneﬁcial to focus on more effective treatments for
sleep/wake and neurodegenerative disorders.
DISCUSSION
Many neurodegenerative diseases result from targeted destruction
of neurotransmitter systems. The co-morbidity of sleep disorders
with neurodegenerative diseases suggests that changes in many of
these neural areas manifests in sleep/wake and circadian dysfunc-
tion. Effects on the sleep/wake and circadian systems may result
from,or contribute to, the increasing pathology. Some research has
shown the beneﬁt of pharmacologically or behaviorally restoring
rhythms and sleep/wake for delaying pathologies (Table 1). This
is important to understand in a society where sleep is not con-
sidered a priority. A few points worth considering are as follows:
Sleep is a basic need that is made secondary to work schedules and
some leisure activities for many adults. In developing children and
adolescents, early school start times and late night extracurricu-
lar meetings contribute to a culture of sleep deprived, cognitively
unhealthy Americans. If restoring our circadian and sleep/wake
cycles can ward off the deterioration of the brain, it is impera-
tive to educate the public about the very real damage of abnormal
sleep/wake cycles not only in aging individuals but at every age.
The fragmented sleep/wake pattern seen in aging individuals
can be due to the degeneration or dysfunction of the circadian
and sleep/wake networks. Uncoupling of the central and periph-
eral oscillators may exacerbate dysfunction via altered feedback
signals or signaling pathways. It is likely that several brain regions
are affected and that there are individual differences in how the
sleep/wake and circadian networks degrade. Additionally there
may be differential plasticity and compensation in the integration
of these neural systems, making the identiﬁcation of applicable
therapies very difﬁcult. However, if mechanisms contributing to
the normal aging process of these networks are identiﬁed, this
may elucidate a general therapy for restoring sleep/wake and cir-
cadian homeostasis. Ultimately this could also reduce the onset or
improve the symptoms of neurodegenerative diseases. It is crucial
that we immediately invest our energies and resources in under-
standing these mechanisms as well as in the dissemination and
implementation of current knowledge and therapies to the public.
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